JP2023523401A5 - - Google Patents

Info

Publication number
JP2023523401A5
JP2023523401A5 JP2022562857A JP2022562857A JP2023523401A5 JP 2023523401 A5 JP2023523401 A5 JP 2023523401A5 JP 2022562857 A JP2022562857 A JP 2022562857A JP 2022562857 A JP2022562857 A JP 2022562857A JP 2023523401 A5 JP2023523401 A5 JP 2023523401A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562857A
Other languages
English (en)
Japanese (ja)
Other versions
JP7713956B2 (ja
JP2023523401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027346 external-priority patent/WO2021211753A1/en
Publication of JP2023523401A publication Critical patent/JP2023523401A/ja
Publication of JP2023523401A5 publication Critical patent/JP2023523401A5/ja
Priority to JP2025118672A priority Critical patent/JP2025157372A/ja
Application granted granted Critical
Publication of JP7713956B2 publication Critical patent/JP7713956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562857A 2020-04-15 2021-04-14 タウ結合化合物 Active JP7713956B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025118672A JP2025157372A (ja) 2020-04-15 2025-07-15 タウ結合化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063010261P 2020-04-15 2020-04-15
US63/010,261 2020-04-15
US202163162976P 2021-03-18 2021-03-18
US63/162,976 2021-03-18
PCT/US2021/027346 WO2021211753A1 (en) 2020-04-15 2021-04-14 Tau binding compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025118672A Division JP2025157372A (ja) 2020-04-15 2025-07-15 タウ結合化合物

Publications (3)

Publication Number Publication Date
JP2023523401A JP2023523401A (ja) 2023-06-05
JP2023523401A5 true JP2023523401A5 (cg-RX-API-DMAC7.html) 2024-04-23
JP7713956B2 JP7713956B2 (ja) 2025-07-28

Family

ID=75787309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562857A Active JP7713956B2 (ja) 2020-04-15 2021-04-14 タウ結合化合物
JP2025118672A Pending JP2025157372A (ja) 2020-04-15 2025-07-15 タウ結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025118672A Pending JP2025157372A (ja) 2020-04-15 2025-07-15 タウ結合化合物

Country Status (10)

Country Link
EP (1) EP4135841A1 (cg-RX-API-DMAC7.html)
JP (2) JP7713956B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230020394A (cg-RX-API-DMAC7.html)
CN (1) CN116249712A (cg-RX-API-DMAC7.html)
AU (1) AU2021257848A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020753A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180222A1 (cg-RX-API-DMAC7.html)
IL (1) IL297200A (cg-RX-API-DMAC7.html)
MX (1) MX2022012752A (cg-RX-API-DMAC7.html)
WO (1) WO2021211753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250243263A1 (en) 2022-06-22 2025-07-31 Voyager Therapeutics, Inc. Tau binding compounds
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
WO2024077170A1 (en) * 2022-10-05 2024-04-11 Shangpharma Innovation, Inc. Anti-urokinase-type plasminogen activator receptor antibodies and methods of use
AU2023364350A1 (en) 2022-10-19 2025-06-05 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2024229389A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2026515970A (ja) * 2023-05-04 2026-05-19 ボイジャー セラピューティクス インコーポレイテッド Aavカプシドバリアント及びその使用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025192556A1 (ja) * 2024-03-12 2025-09-18 学校法人 学習院 タウ凝集体に結合する抗体およびその用途
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US715A (en) 1838-04-28 Improvement in water-wheels
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
ATE286138T1 (de) 1998-03-20 2005-01-15 Univ Pennsylvania Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2000024916A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
JP2003501067A (ja) 1999-06-02 2003-01-14 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヘルパーウイルスを要求する組み換えウイルス産生のために有用な組成物及び方法
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
EP1390490B1 (en) 2001-05-24 2009-04-15 Genzyme Corporation Muscle-specific expression vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
WO2008052322A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
HUE029744T2 (en) 2007-07-26 2017-04-28 Uniqure Ip Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011101869A1 (en) 2010-02-22 2011-08-25 Transgene Biotek Ltd. Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
CA2859665C (en) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
WO2014124282A1 (en) 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
TWI734975B (zh) * 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017189963A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
TW202106705A (zh) 2019-04-29 2021-02-16 美商航海家醫療公司 用於tau蛋白病變之治療之組合物及方法

Similar Documents

Publication Publication Date Title
US10875909B2 (en) Humanized antibodies that recognize alpha-synuclein
JP2023113696A5 (cg-RX-API-DMAC7.html)
EP3378535B1 (en) Humanized antibodies that recognize alpha-synuclein
JP2018519810A5 (cg-RX-API-DMAC7.html)
CN110997715A (zh) 用于治疗突触核蛋白病的组合物和方法
JP2023537761A5 (cg-RX-API-DMAC7.html)
TW202400231A (zh) 治療神經退化性疾病之方法
JP2023523401A (ja) タウ結合化合物
US12291565B2 (en) Tau binding compounds
JP2023554382A5 (cg-RX-API-DMAC7.html)
CN105431203A (zh) 治疗性融合蛋白
JP2025507569A5 (cg-RX-API-DMAC7.html)
US20230107034A1 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
TW202242118A (zh) 抗體遞送
US20240309076A1 (en) Tau-specific antibody gene therapy compositions, methods and uses thereof
EP4701734A2 (en) Methods of treating oxidized phosphatidylcholine-associated diseases
RU2789485C2 (ru) Способы лечения нейродегенеративных заболеваний
WO2025171411A1 (en) Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
HK40116954A (en) Antigen-binding molecules with increased penetration into and retention in brain, and methods for use thereof
HK40112634A (en) Methods of treating tau pathologies
HK1261629A1 (en) Humanized antibodies that recognize alpha-synuclein
HK1261629B (en) Humanized antibodies that recognize alpha-synuclein